Outcome analysis of 18F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 5193-5198

  Ohtaka, Kazuto ^a   Hida, Yasuhiro ^a   Kaga, Kichizo ^a   Okamoto, Shozo ^a   Shiga, Tohru ^a   Tamaki, Nagara ^a   Muto, Jun ^a   Nakada Kubota, Reiko ^a   Hirano, Satoshi ^a   Matsui, Yoshiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG; Lung cancer; Lymph nodes; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; DRUG ACCUMULATION; DRUG UPTAKE; EVALUATION STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; OVERALL SURVIVAL; PARTIAL VOLUME EFFECT; PARTIAL VOLUME EFFECT CORRECTION; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME; VERY ELDERLY;

18F-FDG; LUNG CANCER; LYMPH NODES; PET;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE;

EID: 84891367537     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T: Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42: 139-147, 2012.
3. Vital Statistics in Japan, tabulated by Center for Cancer Control and Information Survices, National Cancer Center, Japan.
4. Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M and Yokoi K; Japanese Joint Committee for Lung Cancer Registration: Japanese Lung Cancer Registry study of 11,663 surgical cases in 2004: Demographic and prognosis changes over decade. J Thorac Oncol 6: 1229-1235, 2011.
5. Lee HJ, Jo J, Son DS, Lee J, Choi YS, Kim K, Shim YM and Kim J: Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection. J Korean Med Sci 24: 824-830, 2009.
6. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM and DeCamp MM: Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer 115: 1059-1069, 2009.
7. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S and Rusch V: Preoperative F-18 fluorodeoxyglucose-positron-emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22: 3255-3260, 2004.
8. Lee J, Aronchick JM and Alavi A: Accuracy of F-18 fluorodeoxyglucose positron-emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: A retrospective review. Chest 120: 1791-1797, 2001.
9. Perigaud C, Bridji B, Roussel JC, Sagan C, Mugniot A, Duveau D, Baron O and Despins P: Prospective preoperative mediastinal lymph node staging by integrated positron-emission tomography-computerized tomography in patients with non-small cell lung cancer. Eur J Cardiothorac Surg 36: 731-736, 2009.
10. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF Jr., Lafitte JJ and Sculier JP; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project: Primary tumor standardized uptake value (SUV max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC). A systematic review and meta-analysis by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3: 6-12, 2008.
11. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, Seki H, Nambu Y, Tonami H and Yamamoto I: FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 41: 85-92, 2000.
12. 18F- FDG PET in patients with non-small cell lung cancer. J Nucl Med 48: 1592-1598, 2007.
13. Yoshioka M and Ichiguchi O: Selection of sublobar resection for c-stage IA non-small cell lung cancer based on a combination of structural imaging by CT and functional imaging by FDG PET. Ann Thorac Cardiovasc Surg 15: 82-88, 2009.
14. Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M and Okada M: Prediction of pathologic nodenegative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg 144: 1365-1371, 2012.
15. Okamoto S, Shiga T, Hattori N, Kubo N, Takei T, Katoh N, Sawamura Y, Nishijima K, Kuge Y and Tamaki N: Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med 25: 213-220, 2011.
16. Soret M, Bacharach SL and Buvat I: Partial-volume effect in PET tumor imaging. J Nucl Med 48: 932-945, 2007.
17. Srinivas SM, Dhurairaj T, Basu S, Bural G, Surti S and Alavi A: A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med 23: 341-348, 2009.
18. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallières E and Wood DE: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6: 3837-3844, 2000.
19. Fahey FH, Kinahan PE, Doot RK, Kocak M, Thurston H and Poussaint TY: Variability in PET quantitation within a multicenter consortium. Med Phys 37: 3660-3666, 2010.
20. Boellaard R: Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50: 11-20, 2009.
21. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, Bastian P, Salskov A, Vallières E and Wood DE: Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 13: 3255-3263, 2007.
22. Vesselle H, Turcotte E, Wiens L, Schmidt R, Takasugi JE, Lalani T, Vallières E and Wood DE: Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron-emission tomography and surgical stage with relevance to patient prognosis. Clin Cancer Res 10: 4709-4716, 2004.
23. Kamibayashi T, Tsuchida T, Demura Y, Tsujikawa T, Okazawa H, Kudoh T and Kimura H: Reproducibility of semi-quantitative parameters in FDG-PET using two different PET scanners: Influence of attenuation correction method and examination interval. Mol Imaging Biol 10: 162-166, 2008.
24. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, van Lanschot J, Sloof G and Boellaard R: Quantification of FDG-PET studies using standardised uptake values in multicentre trials: Effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 34: 392-404, 2007.
25. Okada M, Nakayama H, Okumura S, Daisaki H, Adachi S, Yoshimura M and Miyata Y: Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg 141: 1384-1391, 2011.